Development of nanoparticles for the Novel anticancer therapeutic agents for Acute Myeloid Leukemia

Abstract

Acute myeloid leukaemia is becoming more predominant in blood cancer in geriatrics people groups. In 2017, four new therapeutic candidates have been approved by the FDA: Enasidenib, CPX 351, Midostaurin, and Gemtuzumab ozogamicin; with the approval of Venetoclax and Daurismo, additional advances were achieved in 2018. Ivosidenib and gilteritinib were also accepted as single-agent therapy in persistent and recurrent AML 2018. Most of the anticancer drugs belong to Biopharmaceutical classification system-II (BSC), and BCS class-IV has poor bioavailability because of solubility issues. We will overcome this problem by preparing nanoparticles of this drug by using different nanoparticle preparation methods.